Electronic nose (breathprint) to track treatment response in non-small cell lung cancer
Official title: Electronic Nose (E-nose) Technology to Assess Pathologic Response and Post- Treatment Progression for Non-small Cell Lung Cancer: a Phase II Study
Run by Memorial Sloan Kettering Cancer Center · NCT07218601 · Data updated 2026-11-12
This trial will test whether an electronic nose breath test can detect chemical changes in the breath of adults with non-small cell lung cancer before and after neoadjuvant therapy or surgery.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Locations | 7 sites (Basking Ridge, New Jersey and 6 other locations) |
| Status | Recruiting |
| Started | October 10, 2025 |
| Main results expected | October 2027 |
| Study ends | October 2027 |
| Registry record updated | March 23, 2026 |
| Trial ID | NCT07218601 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with untreated clinical stage I NSCLC planned for upfront surgery or stage II–IIIB NSCLC planned for neoadjuvant therapy followed by surgery and an ECOG performance status of 0–2.
✕Probably not a fit
Patients who are not candidates for surgery or neoadjuvant therapy, who have other histologies of lung cancer, or who cannot attend the study sites are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase 2 interventional study collects breath samples (and optional research blood) to measure volatile chemical patterns using an electronic nose before and after standard neoadjuvant therapy or upfront surgery. Eligible participants include adults with untreated clinical stage I disease planned for surgery or stage II–IIIB disease planned for neoadjuvant therapy followed by surgery. Breathprints will be compared with clinical measures of treatment response such as imaging and surgical pathology to identify changes associated with therapy. The procedure is noninvasive and aims to find reproducible breath biomarkers that correlate with treatment effect.
Why it matters
Potential benefit: If successful, this approach could offer a simple, noninvasive breath test to monitor how well lung cancer treatment is working.
How similar studies have gone: Prior small studies of breathprint and electronic nose technologies have shown promising signals for detecting and monitoring lung cancer, but larger clinical validation remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 * Untreated clinical stage I NSCLC amenable to upfront surgery * Untreated stage II to IIIB NSCLC amenable to neoadjuvant treatment followed by surgery * ECOG Performance Status of ≤2 Of note, the E-nose is a completely noninvasive technology (only breath samples are collected). Therefore, this intervention would have no effects on a developing human fetus. There are therefore no requirements for the study population related to contraception or pregnancy testing.
Where it's running
-
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, United States Recruiting -
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, United States Recruiting -
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, United States Recruiting -
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)
Commack, New York, United States Recruiting -
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, United States Recruiting -
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States Recruiting
Show 1 more location
-
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, New York, United States Recruiting
Study contacts
- Principal investigator: Gaetano Rocco, MD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Gaetano Rocco, MD
- Email: roccog@mskcc.org
- Phone: 212-639-3478
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Patient-specific MRD liquid biopsy for resected NSCLC
This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.
-
Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases
This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.
-
Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies
This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery
This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.
-
HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC
This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.